Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Malaria has been a major global health problem of humans through history and is a leading cause of death and disease across many tropical and subtropical countries. Over the last fifteen years renewed efforts at control have reduced the prevalence of malaria by over half, raising the prospect that elimination and perhaps eradication may be a long-term possibility. Achievement of this goal requires the development of new tools including novel antimalarial drugs and more efficacious vaccines as well as an increased understanding of the disease and biology of the parasite. This has catalyzed a major effort resulting in development and regulatory approval of the first vaccine against malaria (RTS,S/AS01) as well as identification of novel drug targets and antimalarial compounds, some of which are in human clinical trials.

Original publication




Journal article



Publication Date





610 - 624


Adaptive Immunity, Animals, Antimalarials, Communicable Disease Control, Culicidae, Disease Eradication, Drug Resistance, Erythrocytes, Global Health, Host-Parasite Interactions, Humans, Life Cycle Stages, Liver, Malaria Vaccines, Malaria, Falciparum, Merozoites, Plasmodium falciparum, Sporozoites, Vaccines, Synthetic